Classes & Events News Feedback Donate

Overlook Medical Center Offers ‘Next Generation’ 3-D Technology to Improve Prostate Cancer Diagnosis

November 15, 2019

Overlook Medical Center is now offering a highly advanced technology that will enhance the ability of physicians to diagnose, stage and treat prostate cancer. The UroNav Fusion Biopsy System fuses pre-biopsy magnetic resonance imaging (MRI) images of the prostate with ultrasound-guided 3-D images in real time, allowing for excellent imaging of the prostate and any abnormal changes (lesions) that may or may not be cancerous.

“We have strived to provide the latest technologies to benefit our patients,” said Dennis Lowenthal, MD, medical director, Carol G. Simon Cancer Center at Overlook Medical Center. “UroNav’s MRI/ultrasound fusion-guided biopsy is now the latest technology for prostate cancer diagnosis. The quality of imaging enables us to get the most accurate results, and to guide the most effective treatment plan if cancer is found. This is the next generation of prostate cancer detection.”

Prostate cancer is the second most common cancer in men after skin cancer. When caught early, it is highly treatable.

“Prostate specific antigen (PSA) testing and the digital rectal exam (DRE), the most common means of screening for prostate cancer, can be unreliable and can lead to many uncertainties,” said Dr. Lowenthal. “Trans-rectal ultrasound-guided (TRUS) biopsy, which is the current standard for prostate cancer detection when the PSA is elevated or something suspicious is found on DRE, may provide less optimal imaging of both the prostate and biopsy needle, and the needle may pass through tumor-free areas of the prostate, therefore missing the tumor. The UroNav system addresses both of these issues.”

“Radiology data are easily and quickly transferred to UroNav for review and target identification,” said Terrence Lee, MD, a radiologist at Overlook Medical Center. “UroNav helps target suspicious lesions which can increase accuracy in diagnosing prostate cancer.”